BiologicalDrug
Atibuclimab clinical trials
Also written IC14.
- studies test it
- 13
- open now
- 2
- in phase 3
- 0
- first study started
- 2005
Keep track of what changes. Save the atibuclimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- IC14
- 9
Studies by the year they started
12 studies that test it; most in 2019 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Implicit Bioscience (9) · QuantumLeap Healthcare Collaborative (1) · VA Office of Research and Development (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Washington (1)
Often tested with
Tested in the same studies.
Remdesivir (1) · Imatinib (1) · Dexamethasone (1) · Cenicriviroc (1) · Icatibant (1) · Apremilast (1) · Dornase alfa (1) · Celecoxib (1)
Studies
Open first, then newest update. How each study uses atibuclimab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Anti-CD14 Treatment With IC14 in Hospitalized ARDS PatientsRecruitingPhase 2Implicit BioscienceNCT06513949Written as Atibuclimab
- Pilot and Feasibility Study of Anti-CD14 for the Treatment of Knee OsteoarthritisNot yet recruitingPhase 1VA Office of Research and DevelopmentNCT07481474Written as Atibuclimab
- IC14 in Adult Patients With Dengue FeverWithdrawnPhase 2Implicit BioscienceNCT03875560Written as IC14
- IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)WithdrawnPhase 2Implicit BioscienceNCT03474263Written as Biologic: IC14 (monoclonal antibody against human CD14)
- A Phase 2 Study of IC14 in Acute Respiratory Distress SyndromeWithdrawnPhase 2Implicit BioscienceNCT03017547Written as IC14
- IC14 for Treatment of Amyotrophic Lateral SclerosisWithdrawnPhase 2Implicit BioscienceNCT03508453Written as IC14
- IC14 (Atibuclimab) in Arrhythmogenic CardiomyopathyCompletedPhase 1/2Implicit BioscienceNCT06275893Written as IC14
- Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMIActive, not recruitingPhase 1/2Implicit BioscienceNCT06678074Written as Atibuclimab (IC14), 20 mg/kg intravenously, once
- IC14 for Treatment of Acute Decompensated Heart FailureActive, not recruitingPhase 1/2Implicit BioscienceNCT06556810Written as Atibuclimab (IC14)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as IC14
- Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone DiseaseCompletedPhase 1Implicit BioscienceNCT03487263Written as IC14
- COVID-19 and Anti-CD14 Treatment TrialTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04391309Written as anti-CD14
- IC14 Antibodies to Treat Individuals With Acute Lung InjuryTerminatedPhase 2University of WashingtonNCT00233207Written as IC14
Codes
What other systems call atibuclimab · ClinicalTrials.gg INT001734
- MeSH (NLM) C000719996atibuclimabOne source ClinicalTrials.gov
- UNII (FDA) 23IQ3PO968ATIBUCLIMABOne source FDA
- NCI Thesaurus C172657AtibuclimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719996 | atibuclimab | One source ClinicalTrials.gov |
| UNII (FDA) | 23IQ3PO968 | ATIBUCLIMAB | One source FDA |
| NCI Thesaurus | C172657 | Atibuclimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.